Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A T van Oosterom

Showing results (121-130 of 196) with videos related to

Pageof 20
Sort By:
Biomedical & Environmental Mass Spectrometry|November 1, 1987
Monitoring the behaviour of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometryE A de Bruijn, A T van Oosterom, P A Leclercq, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma GroupJ Schütte, H T Mouridsen, W Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyM Van Glabbeke, A T van Oosterom, J W Oosterhuis, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumourW Van de Vrie, E E Gheuens, N M Durante, et al.
Seminars in Oncology|June 8, 2001
Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcomeH Dumez, M Highley, G Guetens, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma GroupW P Steward, J Verweij, R Somers, et al.
Cancer Research|December 15, 1990
Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formationA M Fichtinger-Schepman, S D van der Velde-Visser, H C van Dijk-Knijnenburg, et al.
The Thoracic and Cardiovascular Surgeon|December 1, 1993
Primary mediastinal leiomyosarcomaP E Van Schil, C G Colpaert, R Van Look, et al.
Journal of Chromatography. A|July 26, 2005
Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometryG Guetens, H Prenen, G De Boeck, et al.
The Journal of Pathology|June 1, 1997
Evaluation of tumour angiogenesis as a prognostic marker in malignant mesotheliomaS Kumar-Singh, P B Vermeulen, J Weyler, et al.
Pageof 20

Showing results (121-130 of 196) with videos related to

Sort By:
Pageof 20
Biomedical & Environmental Mass Spectrometry|November 1, 1987
Monitoring the behaviour of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometryE A de Bruijn, A T van Oosterom, P A Leclercq, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma GroupJ Schütte, H T Mouridsen, W Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyM Van Glabbeke, A T van Oosterom, J W Oosterhuis, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumourW Van de Vrie, E E Gheuens, N M Durante, et al.
Seminars in Oncology|June 8, 2001
Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcomeH Dumez, M Highley, G Guetens, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma GroupW P Steward, J Verweij, R Somers, et al.
Cancer Research|December 15, 1990
Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formationA M Fichtinger-Schepman, S D van der Velde-Visser, H C van Dijk-Knijnenburg, et al.
The Thoracic and Cardiovascular Surgeon|December 1, 1993
Primary mediastinal leiomyosarcomaP E Van Schil, C G Colpaert, R Van Look, et al.
Journal of Chromatography. A|July 26, 2005
Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometryG Guetens, H Prenen, G De Boeck, et al.
The Journal of Pathology|June 1, 1997
Evaluation of tumour angiogenesis as a prognostic marker in malignant mesotheliomaS Kumar-Singh, P B Vermeulen, J Weyler, et al.
Pageof 20